Relmada Therapeutics (RLMD) Income from Continuing Operations (2012 - 2026)
Relmada Therapeutics' (RLMD) quarterly Income from Continuing Operations came in at 56426288.0 in Q1 2026, down 216.54% year-on-year from 48417145.0 in Q1 2025, and down 182.54% on a QoQ basis from 19971046.0 in Q4 2025.
Relmada Therapeutics (RLMD) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Income from Continuing Operations data on file, last reported at 56426288.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 216.54% year-over-year to 56426288.0 in Q1 2026; TTM through Mar 2026 was 96377515.0, a 24.78% decrease from a year earlier, with the FY2025 full-year figure at 64619425.0, up 19.72% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 56426288.0, down from 19971046.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for RLMD reached as high as 9899848.0 in Q2 2025 and fell as low as 56426288.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 27708773.18 across 5 years, with a median of 24703820.0 in 2023.
- Across the five-year window, Income from Continuing Operations surged 69.99% in 2022 and sank 216.54% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 39120418.0 in 2022, then jumped by 34.58% to 25592276.0 in 2023, then increased by 27.91% to 18448910.0 in 2024, then slipped by 8.25% to 19971046.0 in 2025, then slumped by 182.54% to 56426288.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 56426288.0 in Q1 2026, 19971046.0 in Q4 2025, and 10080333.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | -56.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.43 Mn |
| Dec 31, 2025 | -19.97 Mn |
| Sep 30, 2025 | -10.08 Mn |
| Jun 30, 2025 | -9.90 Mn |
| Mar 31, 2025 | -17.83 Mn |
| Dec 31, 2024 | -18.45 Mn |
| Sep 30, 2024 | -22.75 Mn |
| Jun 30, 2024 | -18.21 Mn |
| Mar 31, 2024 | -37.08 Mn |
| Dec 31, 2023 | -25.59 Mn |
| Sep 30, 2023 | -21.41 Mn |
| Jun 30, 2023 | -24.70 Mn |
| Mar 31, 2023 | -26.99 Mn |
| Dec 31, 2022 | -39.12 Mn |
| Sep 30, 2022 | -38.74 Mn |
| Jun 30, 2022 | -45.51 Mn |
| Mar 31, 2022 | -38.30 Mn |
| Dec 31, 2021 | -130.38 Mn |
| Sep 30, 2021 | -42.65 Mn |
| Jun 30, 2021 | -26.46 Mn |